| Detailed information |
|---|
| CancerLivER ID | 2036 |
| Biomarker | miR-522 |
| Biomarker Name/Symbol (given in Publication) | mir522 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Predict survival; but not validated on an independent dataset |
| Experimental Condition | HBV-HCC v/s Normal; Can predict survival of patients |
| Cancer type | HBV-associated Hepatocellular carcinoma |
| Regulation | Upregulated in the liver cancer cell lines (0.33 fold) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 28322348 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 93 cases of HBV-HCC and 49 cases of adjacent normal controls and liver cancer cell lines (QGY7703, HepG2, and SMMC7721) and QSG7701, a human normal liver cell line. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HBV-HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |